| 3.95 -0.14 (-3.42%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.93 | 1-year : | 6.82 |
| Resists | First : | 5.07 | Second : | 5.84 |
| Pivot price | 4.6  |
|||
| Supports | First : | 3.84 | Second : | 3.2 |
| MAs | MA(5) : | 4.16 |
MA(20) : | 4.52 |
| MA(100) : | 2.62  |
MA(250) : | 1.96 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 15 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 5.84 | Low : | 0.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ENTO ] has closed above bottom band by 19.7%. Bollinger Bands are 62.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.23 - 4.25 | 4.25 - 4.27 |
| Low: | 3.84 - 3.87 | 3.87 - 3.89 |
| Close: | 3.9 - 3.94 | 3.94 - 3.98 |
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Thu, 16 Oct 2025
Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid - PhillyBurbs
Thu, 16 Oct 2025
$150–200B opportunity: Entero Therapeutics launches Grid AI Corp to make data centers grid‑flexible - Stock Titan
Tue, 14 Oct 2025
From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO) - ACCESS Newswire
Tue, 14 Oct 2025
$2.5B market opportunity: Entero Therapeutics acquires GRID AI to scale grid orchestration - Stock Titan
Tue, 14 Oct 2025
Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It - Yahoo Finance
Tue, 14 Oct 2025
>80% Ownership: Entero Therapeutics Acquires GRID AI to Enter $2.5B Grid-Edge Market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 167 (K) |
| Shares Short P.Month | 76 (K) |
| EPS | -11.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -3.4 % |
| Return on Equity (ttm) | -24.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | -1 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|